# Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

> **NCT06810544** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tango Therapeutics, Inc.** · enrollment: 191 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Glioma Glioblastoma Multiforme
- Glioma, Malignant
- Solid Tumor
- Non-Small Cell Adenocarcinoma
- Lung Cancer
- Brain Tumor

## Interventions

- **DRUG:** TNG456
- **DRUG:** abemaciclib

## Key facts

- **NCT ID:** NCT06810544
- **Lead sponsor:** Tango Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-24
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-09-30
- **Target enrollment:** 191 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06810544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06810544, "Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06810544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*